Protagonist Therapeutics, Inc

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· · 2026 · · 2025 · · 2026 · · 2025
License and collaboration revenue	$274,410	$4,712	$544,253	$38,579
Operating expenses:
Cost of revenue	1,100	—	1,100	—
Research and development	41,274	40,003	130,074	112,932
General and administrative	13,704	11,130	39,629	33,419
Total operating expenses	56,078	51,133	170,803	146,351
Income (loss) from operations	218,332	(46,421)	373,450	(107,772)
Interest income	8,253	7,049	20,558	22,028
Other (expense) income, net	(14)	33	(42)	151
Income (loss) before income tax expense	226,571	(39,339)	393,966	(85,593)
Income tax expense	6,556	—	7,319	172
Net income (loss)	$220,015	$(39,339)	$386,647	$(85,765)
Net income (loss) per share:
Basic	$3.32	$(0.62)	$5.88	$(1.35)
Diluted	$3.07	$(0.62)	$5.43	$(1.35)
Weighted-average shares used to compute net income (loss) per share:
Basic	66,362,300	63,772,332	65,799,973	63,418,522
Diluted	71,731,904	63,772,332	71,242,641	63,418,522

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.